Status:
COMPLETED
BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study
Lead Sponsor:
Bayer
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18-48 years
Phase:
PHASE3
Brief Summary
This study will primarily compare the long-term effects of an early and continued treatment with Betaferon/Betaseron (patients who were treated with active medication during the double-blind BENEFIT s...
Detailed Description
The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer HealthCare Pharmaceuticals Inc.. Bayer HealthCare Pharmaceuticals Inc. is the sponsor of t...
Eligibility Criteria
Inclusion
- Patients who have reached scheduled end of study in BENEFIT, either by developing CDMS or by completing 24 months
Exclusion
- No participation in the initial BENEFIT study
Key Trial Info
Start Date :
August 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2008
Estimated Enrollment :
468 Patients enrolled
Trial Details
Trial ID
NCT00185211
Start Date
August 1 2002
End Date
May 1 2008
Last Update
December 30 2013
Active Locations (94)
Enter a location and click search to find clinical trials sorted by distance.
1
Graz, Austria, 8036
2
Innsbruck, Austria, 6020
3
Vienna, Austria, 1090
4
Brussels, Belgium, 1200